The S&P 500 shook off Iran turmoil, climbing oil prices, economic jitters and AI-spending anxiety to deliver a solid gain of more than 9% in the first half of 2026. Yet a handful of biotech names made that performance look tame. Moderna (MRNA), Revolution Medicines (RVMD) and Axsome Therapeutics (AXSM) each posted double- or even triple-digit returns, racing far ahead of the broader market.
But after such blistering runs, Wall Street’s 12-month consensus price targets paint three starkly different pictures: one stock is flashing a warning signal, another looks almost fully valued, and only one is still being singled out for meaningful upside.
Moderna’s surge has a clear narrative. Emerging from the post-pandemic vaccine slump, the company is guiding for as much as 10% revenue growth this year and is awaiting a crucial regulatory decision on its seasonal flu vaccine — with a target action date of August 5. Longer term, Moderna plans to launch up to three new products by 2028, making the recovery story genuinely attractive.
Wall Street, however, is pumping the brakes. The average analyst price target implies a roughly 40% decline from current levels over the next 12 months. The message is blunt: much of the optimism around the vaccine pipeline may already be priced in, and chasing the stock at these levels carries significant risk.
Revolution Medicines owes its explosive gains to hard clinical data. In a Phase 3 trial for previously treated metastatic pancreatic cancer, its lead asset daraxonrasib delivered a median overall survival of 13.2 months, compared with just 6.7 months for chemotherapy — a result described as unprecedented. The company is now preparing to submit the drug for regulatory review, a step that could reshape the treatment landscape.
Despite the breakthrough, the Street sees little near-term torque left. The consensus forecast points to a meager 2% upside over the coming year, suggesting that the market has already gobbled up most of the good news.
By process of elimination, Axsome emerges as the one name Wall Street is still actively betting on. The average price target calls for an additional 13% gain over the next 12 months.
Axsome focuses on central nervous system disorders, with a portfolio spanning Alzheimer’s disease, migraine and narcolepsy. It already has three commercialized drugs, and two are delivering double-digit growth. The growth runway is unusually well-defined: its lead drug Auvelity, already approved for major depressive disorder, recently won a label expansion for agitation associated with Alzheimer’s disease — a new indication that should begin to materially contribute in the quarters ahead. Symbravo, a migraine therapy approved last year, is ramping up as another revenue driver. Meanwhile, multiple late-stage trials are underway across five therapeutic areas, offering shots at explosive earnings growth if the pipeline delivers.
That mix — commercial-stage cash flows with clear near-term catalysts plus a pipeline rich with optionality — is what makes Axsome stand out in the consensus view.
When biotech stocks rocket into the spotlight, the real question is always whether the catalysts have already been fully priced in. For Moderna, the recovery story is colliding with lofty expectations; for Revolution Medicines, a historic dataset has been quickly absorbed. Axsome, by contrast, is the only one of the three that analysts collectively expect to deliver another double-digit advance, supported by multiple unfolding commercial drivers and freshly approved indications. As always with biotech, clinical and commercial risks remain high — but according to Wall Street’s compass, Axsome is the name still pointing north.
